Local refinement of the SARS-CoV-2 BA.2.86 RBD in complex with TRI2-2 minibinder
Seattle Structural Genomics Center for Infectious Disease (SSGCID)
N-acetyl-beta-D-glucosamine; 2-acetamido-2-deoxy-beta-D-glucose; 2-acetamido-2-deoxy-D-glucose; 2-acetamido-2-deoxy-glucose; N-ACETYL-D-GLUCOSAMINE
The computationally designed TRI2-2 miniprotein inhibitor protects against multiple SARS-CoV-2 Omicron variants.
SARS-CoV-2 BA.2.86 RBD in complex with TRI2-2 minibinder
NLCPFHEVFNATRFASVYAWNRTRISNCVADYSVLYNFAPFFAFKCYGVSPTKLNDLCFTNVYADSFVIKGNEVSQIAPG QTGNIADYNYKLPDDFTGCVIAWNSNKLDSKHSGNYDYWYRLFRKSKLKPFERDISTEIYQAGNKPCKGKGPNCYFPLQS YGFRPTYGVGHQPYRVVVLSFELLHAPATVCGP
ELEEQVMHVLDQVSELAHELLHKLTGEELERAAYFNWWATEMMLELIKSDDEREIREIEEEARRILEHLEELARKGGSEA LEELEKALRELKKSTDELERSTEELEKNPSEDALVENNRLIVENNKIIVEVLRIIAKVLKLEHHHHHH
Severe acute respiratory syndrome coronavirus 2
Seattle Structural Genomics Center for Infectious Disease
NIAID, National Institute of Allergy and Infectious Diseases
National Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)
Sarbecoviruses, Spike glycoprotein, Structural Genomic, inhibitor, viral protein, minibinder, Structural Genomics, Seattle Structural Genomics Center for Infectious Disease, SSGCID